Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease
Author(s)
Diego Andrés Rodríguez Lugo
Martha Carolina Valderrama-Ríos
Ricardo Rabagliati
Domênico Capone
Carlos Álvarez
Fabio Varón-Vega
Laura Cristina Nócua-Báez
Cándida Díaz‐Brochero
Leonardo Enciso-Olivera
Sonia Isabel Cuervo
Luis Thompson
Dora Corzo-León
Luis E. Cuéllar
Erika Paola Vergara
Fernando Riera
Patricia Cornejo‐Juárez
Rita Rojas
Beatriz L. Gómez
Adriana Marcela Celis Ramírez
José Luis Sandoval‐Gutiérrez
Mauricio Sarmiento
Diana Lorena Ochoa
Márcio Nucci
Date Issued
24 de febrero de 2025
Type
Article
Volume
29
Issue
2
Start Page
104517
End Page
104517
Abstract
Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
Subjects